Advances in antidepressants for treating post-stroke depression

References

• Jorgensen TS, Wium-Andersen IK, Wium-Andersen MK, et al. Incidence of depression after stroke, and associated risk factors and mortality outcomes, in a large cohort of Danish patients. JAMA Psychiatry. 2016;73:1032–1040.
   PubMed Web of Science ®Google Scholar
• Ayerbe L, Ayis S, Wolfe CD, et al. Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. Br J Psychiatry. 2013;202:14–21.
   PubMed Web of Science ®Google Scholar
• Hackett ML, Yapa C, Parag V, et al. Frequency of depression after stroke: a systematic review of observational studies. Stroke. 2005;36:1330–1340.
   PubMed Web of Science ®Google Scholar
• Bartoli F, Lillia N, Lax A, et al. Depression after stroke and risk of mortality: a systematic review and meta-analysis. Stroke Res Treat. 2013;2013:862978.
   PubMedGoogle Scholar
• Ayerbe L, Ayis S, Crichton SL, et al. Explanatory factors for the increased mortality of stroke patients with depression. Neurology. 2014;83:2007–2012.
   PubMed Web of Science ®Google Scholar
• Eriksson M, Glader EL, Norrving B, et al. Poststroke suicide attempts and completed suicides: a socioeconomic and nationwide perspective. Neurology. 2015;84:1732–1738.
   PubMed Web of Science ®Google Scholar
• Paolucci S, Ngeh J. Suicide in stroke survivors: frequency and risk factors. Neurology. 2015;84:1724–1725.
   PubMed Web of Science ®Google Scholar
• Pohjasvaara T, Vataja R, Leppavuori A, et al. Depression is an independent predictor of poor long-term functional outcome post-stroke. Eur J Neurol. 2001;8:315–319.
   PubMed Web of Science ®Google Scholar
• Ramasubbu R, Robinson RG, Flint AJ, et al. Functional impairment associated with acute poststroke depression: the Stroke Data Bank Study. J Neuropsychiatry Clin Neurosci. 1998;10:26–33.
   PubMed Web of Science ®Google Scholar
• Kauhanen M, Korpelainen JT, Hiltunen P, et al. Poststroke depression correlates with cognitive impairment and neurological deficits. Stroke. 1999;30:1875–1880.
   PubMed Web of Science ®Google Scholar
• Jorgensen L, Engstad T, Jacobsen BK. Higher incidence of falls in long-term stroke survivors than in population controls: depressive symptoms predict falls after stroke. Stroke. 2002;33:542–547.
   PubMed Web of Science ®Google Scholar
• Paolucci S, Di Vita A, Massicci R, et al. Impact of participation on rehabilitation results: a multivariate study. Eur J Phys Rehabil Med. 2012;48:455–466.
   PubMed Web of Science ®Google Scholar
• Gillen R, Tennen H, McKee TE, et al. Depressive symptoms and history of depression predict rehabilitation efficiency in stroke patients. Arch Phys Med Rehabil. 2001;82:1645–1649.
   PubMed Web of Science ®Google Scholar
• Paolucci S, Antonucci G, Grasso MG, et al. Post-stroke depression, antidepressant treatment and rehabilitation results. A case-control study. Cerebrovasc Dis. 2001;12:264–271.
   PubMed Web of Science ®Google Scholar
• Jonsson AC, Lindgren I, Hallstrom B, et al. Determinants of quality of life in stroke survivors and their informal caregivers. Stroke. 2005;36:803–808.
   PubMed Web of Science ®Google Scholar
• Visser MM, Aben L, Heijenbrok-Kal MH, et al. The relative effect of coping strategy and depression on health-related quality of life in patients in the chronic phase after stroke. J Rehabil Med. 2014;46:514–519.
   PubMed Web of Science ®Google Scholar
• Chemerinski E, Robinson RG, Kosier JT. Improved recovery in activities of daily living associated with remission of poststroke depression. Stroke. 2001;32:113–117.
   PubMed Web of Science ®Google Scholar
• Dong JY, Zhang YH, Tong J, et al. Depression and risk of stroke: a meta-analysis of prospective studies. Stroke. 2012;43:32–37.
   PubMed Web of Science ®Google Scholar
• Gonda X, Pompili M, Serafini G, et al. The role of cognitive dysfunction in the symptoms and remission from depression. Ann Gen Psychiatry. 2015;14:27.
   PubMed Web of Science ®Google Scholar
• Lees R, Fearon P, Harrison JK, et al. Cognitive and mood assessment in stroke research: focused review of contemporary studies. Stroke. 2012;43:1678–1680.
   PubMed Web of Science ®Google Scholar
• Hackett ML, Anderson CS, House A, et al. Interventions for treating depression after stroke. Cochrane Database Syst Rev. 2008;4:CD003437.
   PubMed Web of Science ®Google Scholar
• Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47:e98–e169.
   PubMed Web of Science ®Google Scholar
• Shen X, Liu M, Cheng Y, et al. Repetitive transcranial magnetic stimulation for the treatment of post-stroke depression: a systematic review and meta-analysis of randomized controlled clinical trials. J Affect Disord. 2017;211:65–74.
   PubMed Web of Science ®Google Scholar
• Eng JJ, Reime B. Exercise for depressive symptoms in stroke patients: a systematic review and meta-analysis. Clin Rehabil. 2014;28:731–739.
   PubMed Web of Science ®Google Scholar
• El Husseini N, Goldstein LB, Peterson ED, et al. Depression and antidepressant use after stroke and transient ischemic attack. Stroke. 2012;43:1609–1616.
   PubMed Web of Science ®Google Scholar
• Ruddell M, Spencer A, Hill K, et al. Fluoxetine vs placebo for depressive symptoms after stroke: failed randomised controlled trial. Int J Geriatr Psychiatry. 2007;22:963–965.
   PubMed Web of Science ®Google Scholar
• Serafini G. Neuroplasticity and major depression, the role of modern antidepressant drugs. World J Psychiatry. 2012;2:49–57.
   PubMedGoogle Scholar
• Malberg JE. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des. 2005;11:145–155.
   PubMed Web of Science ®Google Scholar
• Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci. 2006;7:137–151.
   PubMed Web of Science ®Google Scholar
• Encinas JM, Vaahtokari A, Enikolopov G. Fluoxetine targets early progenitor cells in the adult brain. Proc Natl Acad Sci U S A. 2006;103:8233–8238.
   PubMed Web of Science ®Google Scholar
• Wiart L, Petit H, Joseph PA, et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke. 2000;31:1829–1832.
   PubMed Web of Science ®Google Scholar
• Cramer SC. Repairing the human brain after stroke. II. Restorative therapies. Ann Neurol. 2008;63:549–560.
   PubMed Web of Science ®Google Scholar
• Hackett ML, Anderson CS, House AO. Interventions for treating depression after stroke. Cochrane Database Syst Rev. 2004;3:CD003437.
   PubMedGoogle Scholar
• Chen Y, Guo JJ. Meta-analysis of antidepressant treatment for patients with poststroke depression. Stroke. 2006;37:1365–1366.
   PubMed Web of Science ®Google Scholar
• Rayner L, Price A, Evans A, et al. Antidepressants for depression in physically ill people. Cochrane Database Syst Rev. 2010;3:CD007503.
   PubMed Web of Science ®Google Scholar
• Xu XM, Zou DZ, Shen LY, et al. Efficacy and feasibility of antidepressant treatment in patients with post-stroke depression. Medicine (Baltimore). 2016;95:e5349.
   PubMed Web of Science ®Google Scholar
• Towfighi A, Ovbiagele B, El HN, et al. Poststroke depression: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017;48:e30–e43.
   PubMed Web of Science ®Google Scholar
• Boustani M, Campbell N, Munger S, et al. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4:311–320.
   Google Scholar
• Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis. 4th ed. Cambridge University Press; Cambridge, UK, 2013.
   Google Scholar
• Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab. 2002;3:13–37.
   PubMed Web of Science ®Google Scholar
• Choi-Kwon S, Han SW, Kwon SU, et al. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke. 2006;37:156–161.
   PubMed Web of Science ®Google Scholar
• Fruehwald S, Gatterbauer E, Rehak P, et al. Early fluoxetine treatment of post-stroke depression A three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol. 2003;250:347–351.
   PubMed Web of Science ®Google Scholar
• Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000;157:351–359.
   PubMed Web of Science ®Google Scholar
• Murray V, Von Arbin M, Bartfai A, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J Clin Psychiatry. 2005;66:708–716.
   PubMed Web of Science ®Google Scholar
• Spalletta G, Caltagirone C. Sertraline treatment of post-stroke major depression: an open study in patients with moderate to severe symptoms. Funct Neurol. 2003;18:227–232.
   PubMed Web of Science ®Google Scholar
• Karaiskos D, Tzavellas E, Spengos K, et al. Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue. J Neuropsychiatry Clin Neurosci. 2012;24:349–353.
   PubMed Web of Science ®Google Scholar
• Tan S, Huang X, Ding L, et al. Efficacy and safety of citalopram in treating post-stroke depression: a meta-analysis. Eur Neurol. 2015;74:188–201.
   PubMed Web of Science ®Google Scholar
• Gao J, Lin M, Zhao J, et al. Different interventions for post-ischaemic stroke depression in different time periods: A single-blind randomized controlled trial with stratification by time after stroke. Clin Rehabil. 2017;31:78–81.
   Web of Science ®Google Scholar
• Jorge RE, Acion L, Moser D, et al. Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry. 2010;67:187–196.
   PubMed Web of Science ®Google Scholar
• Robinson RG, Jorge RE, Moser DJ, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. Jama. 2008;299:2391–2400.
   PubMed Web of Science ®Google Scholar
• Salter KL, Foley NC, Zhu L, et al. Prevention of poststroke depression: does prophylactic pharmacotherapy work? J Stroke Cerebrovasc Dis. 2013;22:1243–1251.
   PubMed Web of Science ®Google Scholar
• Kim JS, Lee EJ, Chang DI, et al. Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Psychiatry. 2017;4:33–41.
   PubMed Web of Science ®Google Scholar
• Skop BP, Brown Tm. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics. 1996;37:12–16.
   PubMed Web of Science ®Google Scholar
• Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost. 2004;91:119–128.
   PubMed Web of Science ®Google Scholar
• Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology. 2012;79:1862–1865.
   PubMed Web of Science ®Google Scholar
• Howland RH. Antidepressant drugs and the risk of intracranial bleeding: parsing an observational study. J Psychosoc Nurs Ment Health Serv. 2016;54:21–24.
   Web of Science ®Google Scholar
• Lam RW. Antidepressants and QTc prolongation. J Psychiatry Neurosci. 2013;38:E5–E6.
   PubMed Web of Science ®Google Scholar
• Mortensen JK, Johnsen SP, Larsson H, et al. Early antidepressant treatment and all-cause 30-day mortality in patients with ischemic stroke. Cerebrovasc Dis. 2015;40:81–90.
   PubMed Web of Science ®Google Scholar
• Mortensen JK, Larsson H, Johnsen SP, et al. Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke: a nationwide propensity score-matched follow-up study. Stroke. 2013;44:420–426.
   PubMed Web of Science ®Google Scholar
• Ried LD, Jia H, Feng H, et al. Selective serotonin reuptake inhibitor treatment and depression are associated with poststroke mortality. Ann Pharmacother. 2011;45:888–897.
   PubMed Web of Science ®Google Scholar
• Bartoli F, Paolucci S. Association of depression and SSRIs with mortality after stroke. Neurology. 2014;83:1998–1999.
   PubMed Web of Science ®Google Scholar
• Lee YC, Lin CH, Lin MS, et al. Comparison of the effects of serotonin-norepinephrine reuptake inhibitors versus selective serotonin reuptake inhibitors on cerebrovascular events. J Clin Psychiatry. 2016;77:e1–e7.
   PubMed Web of Science ®Google Scholar
• Aiyer R, Barkin RL, Bhatia A. Treatment of neuropathic pain with venlafaxine: a systematic review. Pain Med. 2016.
   PubMed Web of Science ®Google Scholar
• Dahmen N, Marx J, Hopf HC, et al. Therapy of early poststroke depression with venlafaxine: safety, tolerability, and efficacy as determined in an open, uncontrolled clinical trial. Stroke. 1999;30:691–692.
   PubMed Web of Science ®Google Scholar
• Cravello L, Caltagirone C, Spalletta G. The SNRI venlafaxine improves emotional unawareness in patients with post-stroke depression. Hum Psychopharmacol. 2009;24:331–336.
   PubMed Web of Science ®Google Scholar
• Kimura M, Kanetani K, Imai R, et al. Therapeutic effects of milnacipran, a serotonin and noradrenaline reuptake inhibitor, on post-stroke depression. Int Clin Psychopharmacol. 2002;17:121–125.
   PubMed Web of Science ®Google Scholar
• Yamakawa Y, Satoh S, Sawa S, et al. Efficacy of milnacipran on poststroke depression on inpatient rehabilitation. Psychiatry Clin Neurosci. 2005;59:705–710.
   PubMed Web of Science ®Google Scholar
• Tsai CS, Wu CL, Chou SY, et al. Prevention of poststroke depression with milnacipran in patients with acute ischemic stroke: a double-blind randomized placebo-controlled trial. Int Clin Psychopharmacol. 2011;26:263–267.
   PubMed Web of Science ®Google Scholar
• Zhang LS, Hu XY, Yao LY, et al. Prophylactic effects of duloxetine on post-stroke depression symptoms: an open single-blind trial. Eur Neurol. 2013;69:336–343.
   PubMed Web of Science ®Google Scholar
• Davis R, Wilde MI. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs. 1996;5:389–402.
   PubMed Web of Science ®Google Scholar
• Niedermaier N, Bohrer E, Schulte K, et al. Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J Clin Psychiatry. 2004;65:1619–1623.
   PubMed Web of Science ®Google Scholar
• Rampello L, Chiechio S, Nicoletti G, et al. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology (Berl). 2004;173:73–78.
   PubMed Web of Science ®Google Scholar
• Pardini M, Cordano C, Benassi F, et al. Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. Eur Neuropsychopharmacol. 2014;24:939–944.
   PubMed Web of Science ®Google Scholar
• Thome J, Foley P. Agomelatine: an agent against anhedonia and abulia? J Neural Transm (Vienna). 2015;122(Suppl 1):S3–S7.
   PubMed Web of Science ®Google Scholar
• Robinson RG, Jorge RE, Clarence-Smith K. Double-blind randomized treatment of poststroke depression using nefiracetam. J Neuropsychiatry Clin Neurosci. 2008;20:178–184.
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Brockman S, Hatch KK, et al. A randomized, placebo-controlled, double-blind efficacy study of nefiracetam to treat poststroke apathy. J Stroke Cerebrovasc Dis. 2016;25:1119–1127.
   PubMed Web of Science ®Google Scholar
• Hu Y, Xing H, Dong X, et al. Pioglitazone is an effective treatment for patients with post-stroke depression combined with type 2 diabetes mellitus. Exp Ther Med. 2015;10:1109–1114.
   PubMed Web of Science ®Google Scholar
• Lazarus LW, Winemiller DR, Lingam VR, et al. Efficacy and side effects of methylphenidate for poststroke depression. J Clin Psychiatry. 1992;53:447–449.
   PubMed Web of Science ®Google Scholar
• Berkowitz HL. Modafinil in poststroke depression. Psychosomatics. 2005;46:93–94.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor. CNS Spectr. 2014;19:105–109.
   PubMed Web of Science ®Google Scholar
• McCormack PL. Vilazodone: a review in major depressive disorder in adults. Drugs. 2015;75:1915–1923.
   PubMed Web of Science ®Google Scholar
• Mago R, Tripathi N, Andrade C. Cardiovascular adverse effects of newer antidepressants. Expert Rev Neurother. 2014;14:539–551.
   PubMed Web of Science ®Google Scholar
• Citrome L. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant–what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2013;67:1089–1104.
   PubMed Web of Science ®Google Scholar
• Palmer EC, Binns LN, Carey H. Levomilnacipran: a new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder. Ann Pharmacother. 2014;48:1030–1039.
   PubMed Web of Science ®Google Scholar
• Thase ME, Gommoll C, Chen C, et al. Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder. Int Clin Psychopharmacol. 2016;31:332–340.
   PubMed Web of Science ®Google Scholar
• Deardorff WJ, Grossberg Gt. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother. 2014;15:2525–2542.
   PubMed Web of Science ®Google Scholar
• Connolly KR, Thase ME. Vortioxetine: a new treatment for major depressive disorder. Expert Opin Pharmacother. 2016;17:421–431.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Harrison J, Loft H, et al.The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol. 2016. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Harrison JE, Lophaven S, Olsen CK. Which cognitive domains are improved by treatment with vortioxetine? Int J Neuropsychopharmacol. 2016;19:pyw054. Available from: https://academic.oup.com/ijnp/article-lookup/doi/10.1093/ijnp/pyw054
   Web of Science ®Google Scholar
• Chen G, Zhang W, Serenko M. Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin. J Clin Pharmacol. 2015;55:671–679.
   PubMed Web of Science ®Google Scholar
• Carta MG, Pala AN, Finco G, et al. Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option? Clin Pract Epidemiol Ment Health. 2015;11:144–149.
   PubMedGoogle Scholar
• Turner-Stokes L, Hassan N. Depression after stroke: a review of the evidence base to inform the development of an integrated care pathway. Part 2: Treatment alternatives. Clin Rehabil. 2002;16:248–260.
   PubMed Web of Science ®Google Scholar
• SPREAD - Stroke Prevention and Educational Awareness Diffusion: ictus cerebrale: linee guida italiane di prevenzione e trattamento. http://www iso-spread it/.
   Google Scholar
• Paolucci S, Gandolfo C, Provinciali L, et al. Quantification of the risk of post stroke depression: the Italian multicenter observational study DESTRO. Acta Psychiatr Scand. 2005;112:272–278.
   PubMed Web of Science ®Google Scholar
• Hackett ML, Anderson CS. Frequency, management, and predictors of abnormal mood after stroke: the Auckland Regional Community Stroke (ARCOS) study, 2002 to 2003. Stroke. 2006;37:2123–2128.
   PubMed Web of Science ®Google Scholar
• Chen Y, Patel NC, Guo JJ, et al. Antidepressant prophylaxis for poststroke depression: a meta-analysis. Int Clin Psychopharmacol. 2007;22:159–166.
   PubMed Web of Science ®Google Scholar
• Mead GE, Hsieh CF, Lee R, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2012;11:CD009286.
   PubMedGoogle Scholar
• Siepmann T, Penzlin AI, Kepplinger J, et al. Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence. Brain Behav. 2015;5:e00373.
   PubMed Web of Science ®Google Scholar
• Kraglund KL, Mortensen JK, Grove EL, et al. TALOS: a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke. Int J Stroke. 2015;10:985–987.
   PubMed Web of Science ®Google Scholar